JPH082318B2 - Transparent triglyceride substrate solution for measuring colipase and method for measuring colipase activity using the same - Google Patents
Transparent triglyceride substrate solution for measuring colipase and method for measuring colipase activity using the sameInfo
- Publication number
- JPH082318B2 JPH082318B2 JP17812488A JP17812488A JPH082318B2 JP H082318 B2 JPH082318 B2 JP H082318B2 JP 17812488 A JP17812488 A JP 17812488A JP 17812488 A JP17812488 A JP 17812488A JP H082318 B2 JPH082318 B2 JP H082318B2
- Authority
- JP
- Japan
- Prior art keywords
- colipase
- measuring
- transparent
- triglyceride
- lipase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000005311 colipase Human genes 0.000 title claims description 74
- 108020002632 colipase Proteins 0.000 title claims description 74
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 title claims description 58
- 239000000758 substrate Substances 0.000 title claims description 49
- 238000000034 method Methods 0.000 title claims description 31
- 230000000694 effects Effects 0.000 title claims description 26
- 239000000243 solution Substances 0.000 claims description 52
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 41
- 239000004367 Lipase Substances 0.000 claims description 32
- 108090001060 Lipase Proteins 0.000 claims description 30
- 102000004882 Lipase Human genes 0.000 claims description 30
- 235000019421 lipase Nutrition 0.000 claims description 30
- -1 polyoxyethylene Polymers 0.000 claims description 25
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000005516 coenzyme A Substances 0.000 claims description 20
- 229940093530 coenzyme a Drugs 0.000 claims description 20
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims description 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 19
- 239000000194 fatty acid Substances 0.000 claims description 19
- 229930195729 fatty acid Natural products 0.000 claims description 19
- 150000004665 fatty acids Chemical class 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 15
- 239000002736 nonionic surfactant Substances 0.000 claims description 15
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 14
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims description 13
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 238000005259 measurement Methods 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 8
- 229960001456 adenosine triphosphate Drugs 0.000 claims description 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 6
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 claims description 5
- 108020002334 Monoacylglycerol lipase Proteins 0.000 claims description 5
- 239000003613 bile acid Substances 0.000 claims description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 4
- 238000011481 absorbance measurement Methods 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims description 3
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 102000003960 Ligases Human genes 0.000 claims description 2
- 108090000364 Ligases Proteins 0.000 claims description 2
- 239000012472 biological sample Substances 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 74
- 229940040461 lipase Drugs 0.000 description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 7
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 7
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 6
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229940117972 triolein Drugs 0.000 description 6
- 102000004539 Acyl-CoA Oxidase Human genes 0.000 description 5
- 108020001558 Acyl-CoA oxidase Proteins 0.000 description 5
- 102000003992 Peroxidases Human genes 0.000 description 5
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 5
- 108040007629 peroxidase activity proteins Proteins 0.000 description 5
- 102000002281 Adenylate kinase Human genes 0.000 description 4
- 108020000543 Adenylate kinase Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 4
- 208000016222 Pancreatic disease Diseases 0.000 description 4
- 102000013009 Pyruvate Kinase Human genes 0.000 description 4
- 108020005115 Pyruvate Kinase Proteins 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 229960003964 deoxycholic acid Drugs 0.000 description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001819 pancreatic juice Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 4
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 4
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 235000019626 lipase activity Nutrition 0.000 description 3
- 229960002337 magnesium chloride Drugs 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- YWWVWXASSLXJHU-AATRIKPKSA-N (9E)-tetradecenoic acid Chemical compound CCCC\C=C\CCCCCCCC(O)=O YWWVWXASSLXJHU-AATRIKPKSA-N 0.000 description 2
- CUXYLFPMQMFGPL-UHFFFAOYSA-N (9Z,11E,13E)-9,11,13-Octadecatrienoic acid Natural products CCCCC=CC=CC=CCCCCCCCC(O)=O CUXYLFPMQMFGPL-UHFFFAOYSA-N 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- HBOQXIRUPVQLKX-BBWANDEASA-N 1,2,3-trilinoleoylglycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)COC(=O)CCCCCCC\C=C/C\C=C/CCCCC HBOQXIRUPVQLKX-BBWANDEASA-N 0.000 description 2
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 2
- IBSUMVZKDLDAEK-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)propane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCN(CC)C1=CC=CC(C)=C1 IBSUMVZKDLDAEK-UHFFFAOYSA-N 0.000 description 2
- 108010052875 Adenine deaminase Proteins 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 239000006173 Good's buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- HBOQXIRUPVQLKX-UHFFFAOYSA-N linoleic acid triglyceride Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC HBOQXIRUPVQLKX-UHFFFAOYSA-N 0.000 description 2
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920002114 octoxynol-9 Polymers 0.000 description 2
- 208000024691 pancreas disease Diseases 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- IJTNSXPMYKJZPR-UHFFFAOYSA-N parinaric acid Chemical compound CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 description 2
- DTBNBXWJWCWCIK-UHFFFAOYSA-K phosphonatoenolpyruvate Chemical compound [O-]C(=O)C(=C)OP([O-])([O-])=O DTBNBXWJWCWCIK-UHFFFAOYSA-K 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 150000004992 toluidines Chemical class 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229940081852 trilinolein Drugs 0.000 description 2
- PHOLIFLKGONSGY-CSKARUKUSA-N (e)-(3-methyl-1,3-benzothiazol-2-ylidene)hydrazine Chemical compound C1=CC=C2S\C(=N\N)N(C)C2=C1 PHOLIFLKGONSGY-CSKARUKUSA-N 0.000 description 1
- UBEIMDKGOYBUKT-FLIQGJDUSA-N 1,2,3-trilinolenoylglycerol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC UBEIMDKGOYBUKT-FLIQGJDUSA-N 0.000 description 1
- ZGVGTPFSVCXVNJ-UHFFFAOYSA-N 1,3-distearoyl-2-palmitoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC ZGVGTPFSVCXVNJ-UHFFFAOYSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JPJDHKGZXKMWDY-UHFFFAOYSA-N 2,3-bis(sulfanyl)propan-1-ol;butanoic acid Chemical compound CCCC(O)=O.CCCC(O)=O.CCCC(O)=O.OCC(S)CS JPJDHKGZXKMWDY-UHFFFAOYSA-N 0.000 description 1
- LKPFWCPZERQLFI-UHFFFAOYSA-N 2,4,6-trimethylpyridine;hydrochloride Chemical compound Cl.CC1=CC(C)=NC(C)=C1 LKPFWCPZERQLFI-UHFFFAOYSA-N 0.000 description 1
- JADYBWICRJWGBW-UHFFFAOYSA-N 2-hydroxy-3-(tetradecanoyloxy)propyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCC JADYBWICRJWGBW-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- MNIQECRMTVGZBM-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine;7h-purin-6-amine Chemical class NC1=NC=NC2=C1NC=N2.CN1CCCC1C1=CC=CN=C1 MNIQECRMTVGZBM-UHFFFAOYSA-N 0.000 description 1
- MENXRDLDYNLDHE-UHFFFAOYSA-N 3-(3,5-dimethoxyanilino)propane-1-sulfonic acid Chemical compound COC1=CC(NCCCS(O)(=O)=O)=CC(OC)=C1 MENXRDLDYNLDHE-UHFFFAOYSA-N 0.000 description 1
- ZTQGWROHRVYSPW-UHFFFAOYSA-N 3-(n-ethyl-3-methylanilino)-2-hydroxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CC(O)CN(CC)C1=CC=CC(C)=C1 ZTQGWROHRVYSPW-UHFFFAOYSA-N 0.000 description 1
- 102000052553 3-Hydroxyacyl CoA Dehydrogenase Human genes 0.000 description 1
- 108700020831 3-Hydroxyacyl-CoA Dehydrogenase Proteins 0.000 description 1
- FKLSONDBCYHMOQ-UHFFFAOYSA-N 9E-dodecenoic acid Natural products CCC=CCCCCCCCC(O)=O FKLSONDBCYHMOQ-UHFFFAOYSA-N 0.000 description 1
- YWWVWXASSLXJHU-UHFFFAOYSA-N 9E-tetradecenoic acid Natural products CCCCC=CCCCCCCCC(O)=O YWWVWXASSLXJHU-UHFFFAOYSA-N 0.000 description 1
- 108030005571 ADP deaminases Proteins 0.000 description 1
- 102000006267 AMP Deaminase Human genes 0.000 description 1
- 108700016228 AMP deaminases Proteins 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010024957 Ascorbate Oxidase Proteins 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000011426 Enoyl-CoA hydratase Human genes 0.000 description 1
- 108010023922 Enoyl-CoA hydratase Proteins 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 102000057621 Glycerol kinases Human genes 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical group C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 101710163410 Probable glycerol kinase Proteins 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- CLJLWABDLPQTHL-UHFFFAOYSA-N TG(15:0/15:0/15:0) Chemical compound CCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCC CLJLWABDLPQTHL-UHFFFAOYSA-N 0.000 description 1
- 102000002932 Thiolase Human genes 0.000 description 1
- 108060008225 Thiolase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 235000021322 Vaccenic acid Nutrition 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- FEKWQAVCLVORKB-UHFFFAOYSA-N [[3,7-bis(dimethylamino)phenothiazine-10-carbonyl]-(3-methoxybenzoyl)amino]methylcarbamic acid Chemical compound COC=1C=C(C(=O)N(C(=O)N2C3=CC=C(C=C3SC=3C=C(C=CC2=3)N(C)C)N(C)C)CNC(=O)O)C=CC=1 FEKWQAVCLVORKB-UHFFFAOYSA-N 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- CUXYLFPMQMFGPL-SUTYWZMXSA-N all-trans-octadeca-9,11,13-trienoic acid Chemical compound CCCC\C=C\C=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-SUTYWZMXSA-N 0.000 description 1
- CUXYLFPMQMFGPL-FWSDQLJQSA-N alpha-Eleostearic acid Natural products CCCCC=CC=C\C=C\CCCCCCCC(O)=O CUXYLFPMQMFGPL-FWSDQLJQSA-N 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- IJTNSXPMYKJZPR-WVRBZULHSA-N alpha-parinaric acid Natural products CCC=C/C=C/C=C/C=CCCCCCCCC(=O)O IJTNSXPMYKJZPR-WVRBZULHSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- VJLOFJZWUDZJBX-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;chloride Chemical compound [Cl-].OCC[NH2+]CCO VJLOFJZWUDZJBX-UHFFFAOYSA-N 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- KJDZDTDNIULJBE-QXMHVHEDSA-N cetoleic acid Chemical compound CCCCCCCCCC\C=C/CCCCCCCCCC(O)=O KJDZDTDNIULJBE-QXMHVHEDSA-N 0.000 description 1
- XZJZNZATFHOMSJ-KTKRTIGZSA-N cis-3-dodecenoic acid Chemical compound CCCCCCCC\C=C/CC(O)=O XZJZNZATFHOMSJ-KTKRTIGZSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- IXLCRBHDOFCYRY-UHFFFAOYSA-N dioxido(dioxo)chromium;mercury(2+) Chemical compound [Hg+2].[O-][Cr]([O-])(=O)=O IXLCRBHDOFCYRY-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004204 exocrine pancreatic function Effects 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- RBLADLVPSYELCA-KDJFERLWSA-N glycerol 1,3-dioctadecanoate 2-(9z-octadecenoate) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC RBLADLVPSYELCA-KDJFERLWSA-N 0.000 description 1
- 108010054790 glycerol-3-phosphate oxidase Proteins 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- CIPVVROJHKLHJI-UHFFFAOYSA-N n,n-diethyl-3-methylaniline Chemical compound CCN(CC)C1=CC=CC(C)=C1 CIPVVROJHKLHJI-UHFFFAOYSA-N 0.000 description 1
- IAKVKXNIMLQHPA-UHFFFAOYSA-N naphthalen-1-yl hexadecanoate Chemical compound C1=CC=C2C(OC(=O)CCCCCCCCCCCCCCC)=CC=CC2=C1 IAKVKXNIMLQHPA-UHFFFAOYSA-N 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- JSVSNCFSSQRWCK-UHFFFAOYSA-M sodium;2-[(2-aminoacetyl)amino]acetic acid;hydroxide Chemical compound [OH-].[Na+].NCC(=O)NCC(O)=O JSVSNCFSSQRWCK-UHFFFAOYSA-M 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- UWHZIFQPPBDJPM-BQYQJAHWSA-N trans-vaccenic acid Chemical compound CCCCCC\C=C\CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-BQYQJAHWSA-N 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- 229940113164 trimyristin Drugs 0.000 description 1
- 229960001947 tripalmitin Drugs 0.000 description 1
- AURFVNDXGLQSNN-UHFFFAOYSA-K trisodium 2-hydroxypropane-1,2,3-tricarboxylic acid phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O.OC(=O)CC(O)(C(O)=O)CC(O)=O AURFVNDXGLQSNN-UHFFFAOYSA-K 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】 〈産業上の利用分野〉 この発明は生体液中の微量のコリパーゼ、特にヒトの
膵液、血清等のコリパーゼを高感度に効率よく測定する
ための透明なコリパーゼ測定用トリグリセライド基質溶
液とこれを用いたコリパーゼ活性の測定方法に関するも
のである。DETAILED DESCRIPTION OF THE INVENTION <Industrial field of application> The present invention is a transparent triglyceride for measuring colipase for highly sensitive and efficient measurement of a small amount of colipase in a biological fluid, particularly human pancreatic juice, serum and the like. The present invention relates to a substrate solution and a method for measuring colipase activity using the substrate solution.
〈従来の技術と発明が解決しようとする問題点〉 コリパーゼは、リパーゼ活性の発現の必須物質(補酵
素)で、リパーゼはコリパーゼ量により比例的に活性化
される性質を有する。<Problems to be Solved by Conventional Techniques and Inventions> Colipase is an essential substance (coenzyme) for expressing lipase activity, and lipase has the property of being activated proportionally by the amount of lipase.
コリパーゼを測定する必要性を、ヒトの膵より分泌さ
れるコリパーゼを例にして、コリパーゼの性質と共に述
べると次の通りである。The necessity of measuring colipase will be described as follows, together with the properties of colipase, using colipase secreted from human pancreas as an example.
(イ)分子量が約11,000の蛋白質性因子で、生体内では
単独、またはカルシウムイオン、胆汁酸等とも協同して
リパーゼ活性の発現、増強に寄与している。コリパーゼ
の欠損は消化不良、吸収不全の原因となる。(B) A protein factor having a molecular weight of about 11,000, which contributes to the expression and enhancement of lipase activity in vivo alone or in cooperation with calcium ions, bile acids and the like. Deficiency of colipase causes indigestion and malabsorption.
(ロ)急性膵炎、膵臓癌等の膵疾患の指標としては、ア
ミラーゼ、リパーゼを測定する手段が既に採用されてい
るが、コリパーゼは膵外分泌機能の一指標として、また
軽度膵機能障害発見の為の指標として有用である(古川
等:日消誌,83,(7)1367〜1375,1986)。(B) As an indicator of pancreatic diseases such as acute pancreatitis and pancreatic cancer, a method for measuring amylase and lipase has already been adopted, but colipase is used as an indicator of exocrine pancreatic function and for the detection of mild pancreatic dysfunction. It is useful as an index (Furukawa et al .: Nissho, 83, (7) 1367-1375, 1986).
(ハ)膵臓疾患の患者尿、血清中のコリパーゼ/リパー
ゼ量の比率を求め、これを診断へ応用する検討がなされ
ている(ユンゲ等:Clinica.Chimica.Acta.123(1982)2
93〜302)。(C) The ratio of the amount of colipase / lipase in the urine and serum of patients with pancreatic disease is determined, and it is being studied to apply this to diagnosis (Yunge et al .: Clinica.Chimica.Acta.123 (1982) 2
93-302).
以上のように、コリパーゼの測定は臨床学的見地から
有用であるにもかかわらず、現状では積極的にコリパー
ゼを膵疾患の指標として用いる動きはない。その理由
は、従来のコリパーゼの測定法が次の(1)〜(3)に
述べるように、煩雑であり、精度的にも満足のいくもの
ではなかったからである。As described above, although the measurement of colipase is useful from a clinical point of view, there is currently no active use of colipase as an indicator of pancreatic disease. The reason is that the conventional method for measuring colipase is complicated and not satisfactory in accuracy as described in (1) to (3) below.
(1)滴定法 トリグリセライド、主としてオリーブ油、または高級
脂肪酸のグリセロールエステルの懸濁液の基質として、
下記の酵素反応により遊離する脂肪酸をアルカリで滴定
するものである。(1) Titration method As a substrate for a suspension of triglyceride, mainly olive oil, or a glycerol ester of higher fatty acid,
The fatty acid liberated by the following enzyme reaction is titrated with an alkali.
しかし、この方法は反応時間が長く、多量の試料を要
し精度も良好とはいえない。このため、遊離脂肪酸をpH
スタットを用いたり、銅塩として定量する等の改良がな
されたが、相当の時間と労力が必要である。 However, this method has a long reaction time, requires a large amount of sample, and cannot be said to have good accuracy. For this reason, free fatty acids are
Improvements such as using a stat and quantifying as a copper salt have been made, but considerable time and labor are required.
(2)比濁法 (1)の酵素反応による基質の濁りの減少を吸光度で測
定する方法である。(2) Nephelometry This is a method of measuring the decrease in turbidity of the substrate due to the enzymatic reaction of (1) by absorbance.
この方法は簡便ではあるが、濁りの減少とコリパー
ゼ活性が必ずしも一致せず乳化検体では吸光度が逆に上
昇する試料があったりすると、濁りの減少を測定して
コリパーゼ活性を算出するのコリパーゼの間接的測定方
法であること、コリパーゼ活性が低い場合は感度が悪
く、また再現性も良くないこと等の欠点がある。Although this method is simple, if there is a sample in which the decrease in turbidity and the colipase activity do not always match and the absorbance in the emulsified sample rises conversely, the decrease in turbidity can be measured to calculate the colipase activity. However, when the activity of the lipase is low, the sensitivity is poor and the reproducibility is not good.
(3)トリグリセライド以外の人工(合成)基質を使用
して発色剤を用い比色定量するする方法 例えば、BALB(2,3−ジメルカプトプロパン−1−オ
ールトリブチレート)、α−ナフチルパルミテール、モ
ノグリセライド、1,2−ジグリセライド、p−ニトロフ
ェノールラウリン酸エステル、三酪酸ジメチルカプロー
ル等の脂肪酸誘導体、あるいはアルコール誘導体とのエ
ステルを基質として使用するものである。(3) Method for colorimetric determination using a color former using an artificial (synthetic) substrate other than triglyceride For example, BALB (2,3-dimercaptopropan-1-ol tributyrate), α-naphthyl palmitate , A monoglyceride, 1,2-diglyceride, p-nitrophenol lauric acid ester, a fatty acid derivative such as dimethylcaprol tributyrate, or an ester with an alcohol derivative is used as a substrate.
しかし、これらの人工(合成)基質中、非水溶性の物
質には前記(1)、(2)の欠点の他に、これらの人工
基質はリパーゼ−コリパーゼ系以外のエステラーゼによ
っても加水分解されてしまうという基質特異性に問題が
あり、このため阻害剤の添加等が必要となり、また水溶
性の物質にも、前記(2)の欠点は解消されているもの
の、依然としてリパーゼ−コリパーゼ系以外のエステラ
ーゼによっても加水分解されてしまうという基質特異性
の問題は残っている。However, in addition to the disadvantages (1) and (2) described above, the water-insoluble substances in these artificial (synthetic) substrates are hydrolyzed by esterases other than the lipase-colipase system. However, it is necessary to add an inhibitor and the like, and the water-soluble substance has solved the drawback (2), but it is still an esterase other than the lipase-colipase system. The problem of substrate specificity is that it is also hydrolyzed by.
そこで発明者等は、リパーゼ−コリパーゼ系の定義
が第一に長鎖のトリグリセライドを加水分解するもので
あることを重視して、基質としてはトリグリセライドを
使用すること、濁り(基質)の減少を測定するのでは
なく、トリグリセライドがリパーゼ−コリパーゼ系によ
り加水分解して生成した脂肪酸またはグリセロールを直
接測定すること、臨床検査に使用できる簡便な測定方
法であること等を考慮して鋭意研究した結果本発明を完
成した。Therefore, the inventors attach importance to the fact that the definition of the lipase-colipase system firstly hydrolyzes long-chain triglycerides, use triglyceride as a substrate, and measure the decrease in turbidity (substrate). Instead, the result of extensive studies in consideration of direct measurement of fatty acid or glycerol produced by hydrolysis of triglyceride by lipase-colipase system, simple measurement method that can be used in clinical tests, etc. Was completed.
〈問題を解決するための手段〉 本願は次の(I)〜(IX)の請求項から構成されてい
る。<Means for Solving the Problem> The present application comprises the following claims (I) to (IX).
(I)トリグリセライドの均一かつ可溶(透明)化水溶
液にリパーゼを含有させると共に、更にこれに胆汁酸、
塩化カルシウム等のリパーゼ機能促進物質を含有させた
ことを特徴とする透明なコリパーゼ測定用トリグリセラ
イド基質溶液。(I) A uniform and soluble (clear) aqueous solution of triglyceride is allowed to contain lipase, and bile acid,
A transparent triglyceride substrate solution for measuring lipase, which contains a lipase function promoting substance such as calcium chloride.
(II)トリグリセライドの均一かつ可溶(透明)化水溶
液を調製するために使用した界面活性剤が、非イオン界
面活性剤である特許請求の範囲第1項記載の透明なコリ
パーゼ測定用トリグリセライド基質溶液。(II) The transparent triglyceride substrate solution for measuring colipase according to claim 1, wherein the surfactant used for preparing a homogeneous and soluble (clear) aqueous solution of triglyceride is a nonionic surfactant. .
(III)非イオン界面活性剤が、ポリオキシエチレン誘
導体である特許請求の範囲第2項記載の透明なコリパー
ゼ測定用トリグリセライド基質溶液。(IV)非イオン界
面活性剤が、HLB10〜16である特許請求の範囲第2項記
載の透明なコリパーゼ測定用トリグリセライド基質溶
液。(III) The transparent triglyceride substrate solution for measuring colipase according to claim 2, wherein the nonionic surfactant is a polyoxyethylene derivative. The transparent triglyceride substrate solution for measuring colipase according to claim 2, wherein the nonionic surfactant (IV) is HLB 10 to 16.
(V)トリグリセライドを構成する脂肪酸の炭素原子数
が、12〜22個である特許請求の範囲第1項記載の透明な
コリパーゼ測定用トリグリセライド基質溶液。(V) The transparent triglyceride substrate solution for measuring colipase according to claim 1, wherein the fatty acid constituting the triglyceride has 12 to 22 carbon atoms.
(VI)トリグリセライドの均一かつ可溶(透明)化水溶
液のリパーゼの含有量が、測定対象である生体試料のリ
パーゼ含有量より多量である特許請求の範囲第1〜5項
記載の透明なコリパーゼ測定用トリグリセライド基質溶
液。(VI) The transparent lipase measurement according to any one of claims 1 to 5, wherein the content of lipase in the uniform and soluble (clear) aqueous solution of triglyceride is larger than the lipase content of the biological sample to be measured. Substrate solution for triglyceride.
(VII)リパーゼを含有する透明なコリパーゼ測定用ト
リグリセライド基質溶液に、コリパーゼ活性未知のコリ
パーゼを含有する試料を作用させて遊離する脂肪酸また
はグリセロールを、従来公知の吸光度測定法により定量
し、この定量値からコリパーゼ活性を測定することを特
徴とする透明なコリパーゼ測定用トリグリセライド基質
溶液を用いたコリパーゼ活性の測定方法。(VII) A transparent triglyceride substrate solution for lipase measurement containing a lipase-containing sample containing a colipase with unknown colipase activity is used to liberate fatty acids or glycerol, which are quantified by a conventionally known absorbance measurement method. A method for measuring colipase activity using a transparent triglyceride substrate solution for measuring colipase, which comprises measuring colipase activity.
(VIII)遊離する脂肪酸に対し、アデノシン3リン酸
(ATP)、及びコエンザイムA(CoA)の存在下にアルシ
コエンザイムAシンセターゼ(ACS)を反応させて生成
する、(1)アデノシン1リン酸(AMP)、(2)アシ
ルCoA、または(3)前記反応において残存するCoAのう
ちの一成分を、従来公知の吸光度測定法により定量し、
この定量値からコリパーゼ活性を測定する特許請求の範
囲第(VII)項記載の透明なコリパーゼ測定用トリグリ
セライド基質溶液を用いたコリパーゼ活性の測定方法。(VIII) Adenosine triphosphate (AMP) produced by reacting free fatty acid with adenosine triphosphate (ATP) and arsicoenzyme A synthetase (ACS) in the presence of coenzyme A (CoA). ), (2) acyl CoA, or (3) one component of the CoA remaining in the reaction is quantified by a conventionally known absorbance measurement method,
The method for measuring colipase activity using the transparent triglyceride substrate solution for measuring colipase according to claim (VII), wherein the colipase activity is measured from this quantitative value.
(IX)遊離するグリセロールを検出するときは、反応系
にモノグリセライドリパーゼを更に存在させる特許請求
の範囲第(VII)項記載の透明なコリパーゼ測定用トリ
グリセライド基質溶液を用いたコリパーゼ活性の測定方
法。(IX) The method for measuring colipase activity using the transparent triglyceride substrate solution for measuring lipase according to claim (VII), wherein monoglyceride lipase is further present in the reaction system when detecting free glycerol.
前記した本願の透明なコリパーゼ測定用トリグリセラ
イド基質溶液は、比色定量する際に障害とならない程度
の、トリグリセライドの均一かつ可溶(透明)加水溶液
であって、この溶液にリパーゼ(遊離するグリセロール
を測定する場合必要に応じてモノゴリセライドリパーゼ
を含む)を予じめ添加したものである。The above-mentioned transparent triglyceride substrate solution for measuring colipase of the present application is a uniform and soluble (transparent) water solution of triglyceride that does not hinder colorimetric determination, and lipase (free glycerol In the case of measurement, if necessary, monoglyceride lipase is included) was added in advance.
また、この溶液を用いたコリパーゼ活性の測定方法
は、これに濃度未知のコリパーゼを添加して、コリパー
ゼの含有量に比例して、トリグリセライドがリパーゼ−
コリパーゼ系によって加水分解して生ずる遊離脂肪酸、
またはグリセロールを測定するものである。In addition, the method for measuring colipase activity using this solution was to add colipase of unknown concentration to the solution, and triglyceride was converted to lipase-lipase in proportion to the content of colipase.
Free fatty acids generated by hydrolysis by colipase system,
Or it measures glycerol.
従来、トリグリセライドを均一かつ可溶(透明)化水
溶液とする方法は、「非水溶性物質の可溶化水溶液の製
造方法」として特公昭59-39168号公報(特許第127160
号)、特開昭63-91136が公表されているが、この方法に
より得られたトリグリセライドの透明水溶液を、前記し
た欠点を全て解消したコリパーゼ測定用の基質として利
用するのは本願が最初であり、またこの透明水溶液のト
リグリセライドからリパーゼ−コリパーゼ系により遊離
する脂肪酸、またはグリセロールを直接定量してコリパ
ーゼ活性を測定するのは本発明が最初である。Conventionally, a method of uniformly and solubilizing (clearing) triglyceride is disclosed in Japanese Patent Publication No. 59-39168 (Patent No. 127160) as "Method for producing solubilized aqueous solution of water-insoluble substance".
No. 63,91136), but the present application is the first to utilize the transparent aqueous solution of triglyceride obtained by this method as a substrate for measuring colipase in which all the above-mentioned drawbacks are solved. Further, the present invention is the first to directly measure the amount of fatty acid or glycerol liberated by the lipase-colipase system from triglyceride in this clear aqueous solution to measure the colipase activity.
前記した本願の透明なコリパーゼ測定用トリグリサセ
ライド基質溶液は、比色定量する際に障害とならない程
度の、トリグリセライドの均一かつ可溶(透明)化水溶
液(5mM〜1M pH6.0〜9.0)であって、この溶液にリパー
ゼ(過剰量)、及び必要に応じて胆汁酸(コール酸、デ
オキシコール酸、リトコール酸、グリココール酸、タウ
ロコール酸等の塩 1mM〜100mM)、塩化カルシウム(1m
M〜150mM)等を予じめ添加したものである。The above-mentioned transparent triglyceride substrate solution for measuring colipase of the present application is a uniform and solubilized (clear) aqueous solution of triglyceride (5 mM to 1 M pH 6.0 to 9.0), which does not hinder the colorimetric determination. This solution contains lipase (excess amount) and, if necessary, bile acid (salts such as cholic acid, deoxycholic acid, lithocholic acid, glycocholic acid, taurocholic acid 1 mM-100 mM), calcium chloride (1 m
M to 150 mM) etc. are added beforehand.
また、この溶液を用いたコリパーゼ活性の測定方法
は、これに濃度未知のコリパーゼを添加して、コリパー
ゼの含有量に比例して、トリグリセライドがリパーゼ−
コリパーゼ系によって加水分解して生ずる遊離脂肪酸、
またはグリセロールを測定するものである。In addition, the method for measuring colipase activity using this solution was to add colipase of unknown concentration to the solution, and triglyceride was converted to lipase-lipase in proportion to the content of colipase.
Free fatty acids generated by hydrolysis by colipase system,
Or it measures glycerol.
本発明に使用される脂肪酸は、炭素原子数が12〜22個
の次に示す脂肪酸が適している。As the fatty acid used in the present invention, the following fatty acid having 12 to 22 carbon atoms is suitable.
(1)飽和脂肪酸 ラウリン酸、ミリスチン酸、パルミチン酸、ステアリ
ン酸、アラキン酸、ベヘン酸 (2)不飽和脂肪酸 リンデル酸、ラウロレイン酸、ツヅ酸、フィセトレイ
ン酸、ミリストレイン酸、パルミトオレイン酸、ペトロ
セリン酸、オレイン酸、エライジン酸バクセン酸、リノ
ール酸、リノレン酸、α−エレオステアリン酸、β−エ
レオステアリン酸、ブニカ酸、パリナリン酸、カドレイ
ン酸、セトレイン酸、エルカ酸、アラキドン酸等が挙げ
られる。トリグリセライドのR,R′,R″がこれら脂肪酸
によりエステル化されたトリグリセライドとしては次の
ものが例としてあげられる。(1) Saturated fatty acid lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid (2) Unsaturated fatty acid Lindelic acid, lauroleic acid, tudzuic acid, ficetrain acid, myristoleic acid, palmitooleic acid, petrothelin Acid, oleic acid, elaidic acid vaccenic acid, linoleic acid, linolenic acid, α-eleostearic acid, β-eleostearic acid, bunic acid, parinaric acid, caderic acid, cetoleic acid, erucic acid, arachidonic acid and the like. To be Examples of triglycerides in which R, R ′, R ″ of triglyceride are esterified with these fatty acids include the following.
トリラウレイン(結合脂肪酸の炭素数12,12,12), トリデカノイン(13,13,13), トリミリスチン,(14,14,14), トリペンタデカノイン(15,15,15), トリパルミチン(16,16,16), トリマーガリン(17,17,17), トリステアリン(18,18,18), トリノオナデカノイン(19,19,19), トリオレイン(18,18,18), トリライデン(18,18,18), トリリノレイン(18,18,18), トリリノレニン(18,18,18,), トリエルシン(22,22,22), トリブラシジン(22,22,22), 1−ラウロディミリスチン(12,14,14), 1−ミリストディパルミチン(14,16,16), 1−パルミトディステアリン(16,18,18), 1−ステアロディパルミチン(16,16,18), 2−ステアロディパルミチン(16,18,16), 2−パルミトディステアリン(18,16,18), 1−オレオディステアリン(18,18,18), 1−リノレオディステアリン(18,18,18), 2−オレオディステアリン(18,18,18), 1−ステアロディオレイン(18,18,18), 1−ステアロディリノレイン(18,18,18), 1−ステアロ−2ミリスト−3パルミチン(18,14,1
6), 1−ステアロ−2パルミト−3ミリスチン(18,16,1
4), 1ラウロ−2ミリスト−3パルミチン(12,14,16)。Trilaurein (12,12,12 carbon atoms in bound fatty acids), Tridecanoin (13,13,13), Trimyristin, (14,14,14), Tripentadecanoin (15,15,15), Tripalmitin (16 , 16,16), trimergarin (17,17,17), tristearin (18,18,18), trino-ondecanoin (19,19,19), triolein (18,18,18), trileiden (18,18,18), Trilinolein (18,18,18), Trilinolenin (18,18,18,), Triercine (22,22,22), Tribrazidine (22,22,22), 1-lauro Dimyristin (12,14,14), 1-myristodipalmitin (14,16,16), 1-palmitodistearin (16,18,18), 1-stearodipalmitin (16,16,18), 2-stearodipalmitin (16,18,16), 2-palmitodistearin (18,16,18), 1-oleodiestearin (18,18,18), 1-linoleode Stearin (18,18,18), 2-Oleodistearin (18,18,18), 1-Stearodiolein (18,18,18), 1-Stearodilinolein (18,18,18), 1 -Stearo-2 myristo-3 palmitin (18,14,1
6), 1-stearo-2 palmito-3 myristin (18,16,1
4), 1 lauro-2 myristo-3 palmitin (12,14,16).
このうちヒトのリパーゼ−コリパーゼ系を測定しよう
とする場合その基質としては、生体中に多く含まれる脂
肪酸を含むトリグリセライドが望ましく、その例として
はミリスチン酸、パルミチン酸、ステアリン酸、パルミ
トオレイン酸、オレイン酸、リノール酸等であり、中で
も天然に最も広く最も大量に存在する脂肪酸であり、ヒ
ト生体内でも一番多いとされているオレイン酸を含むト
リグリセライドは好ましい基質である。Of these, as a substrate when trying to measure the human lipase-colipase system, triglyceride containing fatty acids contained in a large amount in the living body is desirable, and examples thereof include myristic acid, palmitic acid, stearic acid, palmitooleic acid, Among them, oleic acid, linoleic acid, etc., among them, the fatty acid which is the most widespread and most abundant in nature, and triglyceride containing oleic acid, which is said to be the most abundant in human body, is a preferable substrate.
また、本発明のトリグリセライドの透明な基質溶液を
得るために使用される界面活性剤は、非イオン界面活性
剤であり、ポリオキシエチレンラウリルエーテル、ポリ
オオキシエチレンセチルエーテル、ポリオキシエチレン
ステアリルエーテル、ポリオキシエチレンオレインエー
テル、ポリオキシエチレンオクチルフェニルエーテル、
ポリオキシエチレンノニルフェニルエーテル、ポリオキ
シエチレンポリオキシプロピレンブロックポリマー、ポ
リオキシエチレン高級アルコール等のポリオキシエチレ
ンの誘導体が挙げられ、そのHLBは10〜16の間のものが
適当である。中でもポリオキシエチレン高級アルコール
(HLB10〜16)のものはリパーゼ反応に最適なものとし
て選ばれる。Further, the surfactant used to obtain the transparent substrate solution of triglyceride of the present invention is a nonionic surfactant, such as polyoxyethylene lauryl ether, polyooxyethylene cetyl ether, polyoxyethylene stearyl ether, and polyoxyethylene stearyl ether. Oxyethylene olein ether, polyoxyethylene octyl phenyl ether,
Derivatives of polyoxyethylene such as polyoxyethylene nonyl phenyl ether, polyoxyethylene polyoxypropylene block polymer, and polyoxyethylene higher alcohol are mentioned, and those having an HLB of 10 to 16 are suitable. Among them, polyoxyethylene higher alcohols (HLB10 to 16) are selected as the most suitable for the lipase reaction.
本発明において、トリグリセライドの透明な基質溶液
を得るには、まず非イオン界面活性剤を蒸溜水あるいは
緩衝液に溶解し非イオン界面活性剤の曇点以上に加熱し
トリグリセライドを加え攪拌を続けながら溶解するとい
う方法をとる。In the present invention, in order to obtain a transparent substrate solution of triglyceride, first, a nonionic surfactant is dissolved in distilled water or a buffer solution and heated above the cloud point of the nonionic surfactant, and triglyceride is added and dissolved while continuing stirring. Take the method of doing.
また場合により非イオン界面活性剤を蒸溜水、あるいは
緩衝液に溶解し、更にリパーゼ−コリパーゼ系反応に影
響に無いビルダーを添加しトリグリセライドを加え、室
温にて攪拌を続け最後に蒸溜水あるいは緩衝液で希釈し
て透明な液を得ることもできる。In some cases, a nonionic surfactant is dissolved in distilled water or a buffer solution, a builder that does not affect the lipase-colipase reaction is added, triglyceride is added, and stirring is continued at room temperature. Finally, distilled water or a buffer solution is added. It is also possible to obtain a transparent liquid by diluting with.
この際、過剰の非イオン界面活性剤はリパーゼ−コリ
パーゼ系反応を阻害する場合もあるので、蒸溜水100重
量%に対し、非イオン界面活性材5〜20重量%、トリオ
レイン0.05〜0.5重量%の割合で使用することが望まし
い。At this time, since an excessive amount of nonionic surfactant may inhibit the lipase-colipase system reaction, 5 to 20% by weight of nonionic surfactant and 0.05 to 0.5% by weight of triolein relative to 100% by weight of distilled water. It is desirable to use it in the ratio of.
本発明の可溶化したトリグリセライドのリパーゼ−コ
リパーゼ系反応はpH6.5〜9.0の範囲で反応させることが
好ましく、緩衝液として例えばクエン酸−リン酸ナトリ
ウム緩衝液、イミダゾール塩酸緩衝液、トリエタノール
アミン塩酸−水酸化ナトリウム緩衝液、トリス緩衝液、
グリシルグリシン−水酸化ナトリウム緩衝液、ジエタノ
ールアミン−塩酸緩衝液、ホウ酸緩衝液、2,4,6−トリ
メチルピリジン−塩酸緩衝液、リン酸緩衝液、グッドの
緩衝液等を5mMから300mMぐらいの濃度で使用するのが好
ましい。The lipase-colipase system reaction of the solubilized triglyceride of the present invention is preferably carried out in the range of pH 6.5 to 9.0, and examples of the buffer include citric acid-sodium phosphate buffer, imidazole hydrochloric acid buffer, triethanolamine hydrochloric acid. -Sodium hydroxide buffer, Tris buffer,
Glycylglycine-sodium hydroxide buffer, diethanolamine-hydrochloric acid buffer, borate buffer, 2,4,6-trimethylpyridine-hydrochloric acid buffer, phosphate buffer, Good's buffer, etc. It is preferred to use it in a concentration.
更に本発明では胆汁酸が必須であり、胆汁酸塩として
コール酸、デオキシコール酸、リトコール酸、グリココ
ールレ酸、タウロコール酸等の塩を基質液中に1mM〜100
mMの範囲で添加すると効果的である。また必要に応じ塩
化カルシウムを1mM〜80mMおよび塩化ナトリウムを5mM〜
500mMの割合で基質反応液中に添加すると一層効果的で
ある。Furthermore, in the present invention, bile acid is essential, and cholic acid, deoxycholic acid, lithocholic acid, glycocholleic acid, taurocholic acid and the like as a bile salt are contained in the substrate solution at 1 mM to 100 mM.
It is effective to add in the range of mM. If necessary, calcium chloride 1 mM to 80 mM and sodium chloride 5 mM to
It is more effective if it is added to the substrate reaction solution at a ratio of 500 mM.
このようにして得られた本発明に係るコリパーゼ測定
用試薬は、コリパーゼ活性を測定する試薬として非常に
有効で安定な組成物である。The thus obtained reagent for measuring colipase according to the present invention is a very effective and stable composition as a reagent for measuring colipase activity.
本発明によれば、トリグリセライドの均一かつ可溶
(透明)化水溶液にリパーゼを添加して(含有させて)
製造した透明なコリパーゼ測定用トリグリセライド基質
溶液に、活性が未知のコリパーゼを添加して、リパーゼ
−コリパーゼ系反応により加水分解されて生成する脂肪
酸を、アデノシン3リン酸(ATP)コエンザイムA(Co
A)存在下で脂肪酸にアシルCoAシンセターゼ(ACS)を
作用させる反応を基本としその後、1)生成したアデノ
シン1リン酸(AMP)を測定する。2)生成したアシルC
oAを測定する。3)残存CoAを測定する方法をとること
ができる。According to the present invention, lipase is added (contained) to a uniform and solubilized (clear) aqueous solution of triglyceride.
To the produced transparent triglyceride substrate solution for measuring colipase, a lipase of unknown activity was added to produce a fatty acid produced by hydrolysis by a lipase-colipase system reaction, and adenosine triphosphate (ATP) coenzyme A (Co
A) Based on the reaction of reacting fatty acid with acyl CoA synthetase (ACS) in the presence, 1) produced adenosine monophosphate (AMP) is measured. 2) Acyl C produced
Measure oA. 3) A method of measuring the residual CoA can be adopted.
これらの測定法の例をあげると、1)ではアデノシン
1リン酸(AMP)をアデノシン3リン酸(ATP)、ホスフ
ォエノールピルビン酸(PEP)の共存下でミオキナーゼ
(MK)、ピルビン酸キナーゼ(PK)を作用させてピルビ
ン酸を生成させ、生じたピルビン酸を乳酸脱水素酵素
(LDH)を用いニコチンアミドアデニンジヌクレオチド
−還元型(NADH)の減少を測定する。あるいはピルビン
酸酸化酵素(POP)を用いた比色法で測定する。Examples of these measurement methods include 1) adenosine monophosphate (AMP) in the presence of adenosine triphosphate (ATP) and phosphoenolpyruvate (PEP), myokinase (MK) and pyruvate kinase ( PK) is caused to act to generate pyruvic acid, and the resulting pyruvic acid is measured for reduction of nicotinamide adenine dinucleotide-reduced form (NADH) using lactate dehydrogenase (LDH). Alternatively, it is measured by a colorimetric method using pyruvate oxidase (POP).
あるいは 1)ではADPデアミナーゼを使用してアンモニアを測定
する方法、あるいはAMPデアミナーゼを使用してアンモ
ニアを測定する方法、あるいはAMP又クレオチダーゼ、
アデニンデアミナーゼを作用させてアンモニアを測定す
る方法、更にはAMPピロホスホリラーゼ、アデニンデア
ミナーゼを作用させアンモニアを測定する方法等も例と
してあげられる。 Or In 1), a method of measuring ammonia using ADP deaminase, or a method of measuring ammonia using AMP deaminase, or AMP or cleotidase,
Examples thereof include a method of measuring ammonia by causing adenine deaminase to act, and a method of measuring ammonia by causing AMP pyrophosphorylase and adenine deaminase to act.
2)アシルCoAを測定する方法としてはアシルCoAにアシ
ルCoAオキシダーゼ(ACO)を作用させ生成した過酸化水
素をペルオキシダーゼあるいはカタラーゼの系にもって
いき測定する等の例があげられる。2) Examples of the method for measuring acyl CoA include an example in which the hydrogen peroxide produced by reacting acyl CoA with acyl CoA oxidase (ACO) is transferred to a system of peroxidase or catalase, and the like.
生成した過酸化水素をカタラーゼ、ペルオキシダーゼ
等を用いて測定する。 The produced hydrogen peroxide is measured using catalase, peroxidase, or the like.
生成した過酸化水素を4−アミノアンチピリンと各種
のカプラーと酸化縮合させる。そのカプラーの例として
はフェノールの他アニリン系あるいはトルイジン系等が
あり例えばN−エチル−N−スルホプロピル−m−トル
イジン、N,N−ジエチル−m−トルイジン、3−メチル
−N−エチル−N−(β−ヒドロキシエチル)−アニリ
ン、N−エチル−N−(2−ヒドロキシ−3−スルホプ
ロピル)−m−トルイジン、3,5−ジメトキシ−N−
(3−スルホプロピル)アニリン等がありその他4−ア
ミノアンチピリンの代わりに3−メチル−2−ベンゾチ
アゾリノンヒドラゾンを用いる、あるいは4−アミノア
ンチピリンを使用しない10−(3−メトキシカルボキシ
ル−アミノメチル−ベンゾイル−カルバモイル)−3.7
−ビス(ジメチル−3nk)−10H−フェノチアジン、3−
ビス(4−クロロフェニル)メチル−4−ジメチル−ア
ミノフェニルアミン等のカプラーを用いてもよい。又直
接アシルCoAを脂肪酸代謝の主経路であるβ酸化系すな
わち、アシルCoAをアシルCoAオキシダーゼにて2−3ト
ランス−エノイルCoAにした後、エノイルCoAヒドラター
ゼ、3−ヒドロキシアシルCoAデヒドロゲナーゼ、3−
ケトアシルCoAチオラーゼを作用させNADHの増加を測定
してもよい。The generated hydrogen peroxide is oxidatively condensed with 4-aminoantipyrine and various couplers. Examples of such couplers include aniline type and toluidine type in addition to phenol, such as N-ethyl-N-sulfopropyl-m-toluidine, N, N-diethyl-m-toluidine, 3-methyl-N-ethyl-N. -(Β-hydroxyethyl) -aniline, N-ethyl-N- (2-hydroxy-3-sulfopropyl) -m-toluidine, 3,5-dimethoxy-N-
(3-Sulfopropyl) aniline, etc. Others 3-methyl-2-benzothiazolinone hydrazone is used in place of 4-aminoantipyrine, or 4-aminoantipyrine is not used 10- (3-methoxycarboxyl-aminomethyl -Benzoyl-carbamoyl) -3.7
-Bis (dimethyl-3nk) -10H-phenothiazine, 3-
A coupler such as bis (4-chlorophenyl) methyl-4-dimethyl-aminophenylamine may be used. In addition, the β-oxidation system, which is the main pathway of fatty acid metabolism, directly converts acyl CoA into 2-3 trans-enoyl CoA with acyl CoA oxidase, and then enoyl CoA hydratase, 3-hydroxyacyl CoA dehydrogenase, 3-
The increase of NADH may be measured by acting with ketoacyl-CoA thiolase.
3)の残存するCoAを測定する方法としては残存するCoA
をSH基定量試薬である5,5′−ジチオビス−2−ニトロ
安息香酸(DTNB)等で測定することができる。Remaining CoA as a method for measuring the remaining CoA in 3)
Can be measured with an SH group quantification reagent such as 5,5′-dithiobis-2-nitrobenzoic acid (DTNB).
これら脂肪酸を測定する系の他、リパーゼ反応により
生じたグリセロールを測定してもよく、この場合はトリ
グリセライドのリパーゼ反応は1または3位で行なわ
れ、1,2−ジグリセライドとなり、更にこれが2−モノ
グリセライドとなり最後にグリセロールとなるが、2−
モノグリセライドからグリセロールの反応は起こり難い
ため、モノグリセライドリパーゼを併用すると効果的で
ある。 In addition to the system for measuring these fatty acids, glycerol produced by the lipase reaction may be measured. In this case, the lipase reaction of triglyceride is carried out at the 1- or 3-position to give 1,2-diglyceride, which is then 2-monoglyceride. And finally glycerol, but 2-
Since reaction of glycerol from monoglyceride is unlikely to occur, it is effective to use monoglyceride lipase together.
次に本発明を実施例をもって説明する。 Next, the present invention will be described with reference to examples.
〈実施例1〉 (A)試薬の調整 試薬(1) 蒸留水90mlに非イオン界面活性剤としてエマルゲン70
9(花王アトラス社の商品名、ポリオキシエチレン高級
アルコール曇点56℃)10gを溶解し、56℃以上に加熱す
ると液は曇点に達し白濁する。そこへトリオレイン2gを
添加し56℃以上を保ちながら約30分間攪拌し、その後加
熱をやめ攪拌を続けながら放置する。液は室温に近づく
と透明となるので、この透明となった時点で蒸留水にて
10倍希釈し透明な水溶液を得る(トリオレイン可溶化基
質溶液)。これに豚由来のリバーゼ精製品4,400U、塩化
カルシウム700mgを添加する(透明なコリパーゼ測定用
トリグリセライド基質溶液)。<Example 1> (A) Preparation of reagent Reagent (1) Emulgen 70 as a nonionic surfactant in 90 ml of distilled water
When 9 g of 9 (trade name of Kao Atlas, polyoxyethylene higher alcohol cloud point 56 ° C) is dissolved and heated to 56 ° C or higher, the liquid reaches the cloud point and becomes cloudy. Add 2 g of triolein there and stir for about 30 minutes while maintaining at 56 ° C or higher, then stop heating and leave while stirring. The liquid becomes transparent as it approaches room temperature, so use distilled water when it becomes transparent.
Dilute 10 times to obtain a clear aqueous solution (triolein solubilized substrate solution). To this, 4,400 U of swine-derived purified lipase and 700 mg of calcium chloride are added (transparent triglyceride substrate solution for measuring colipase).
試薬(2) 下記の物質を50mMトリス塩酸緩衝液(pH7.9)にて100
mlとする。Reagent (2) 100 mM of the following substances with 50 mM Tris-HCl buffer (pH 7.9)
ml.
前記トリオレイン可溶化基質溶液:20ml アデノシン−5′−三リン酸(ATP):8.6ml ホスホエノールピルビン酸(PEP):200mg 還元型ニコチンアデニンヌクレオチド(NADH):450mg ミオキナーゼ(MK):214mg ピルビン酸キナーゼ(PK):15000U 乳酸脱水素酵素(LDH):20000U コエンザイムA(CoA):1900mg デオキシコール酸Na(SDC):2000mg アシルコエンザイムAシンセターゼ(ACS):160U 塩化マグネシウム:100mg 試薬(3)(コリパーゼ標準溶液) 30000U/mgのコリパーゼを生理食塩水稀釈し、5,10,1
5,20,25,30,35,40ng/mlとなるように稀釈した。Triolein-solubilized substrate solution: 20 ml Adenosine-5'-triphosphate (ATP): 8.6 ml Phosphoenolpyruvate (PEP): 200 mg Reduced nicotine adenine nucleotide (NADH): 450 mg Myokinase (MK): 214 mg Pyruvate Kinase (PK): 15000U Lactate dehydrogenase (LDH): 20000U Coenzyme A (CoA): 1900mg Deoxycholate Na (SDC): 2000mg Acyl coenzyme A synthetase (ACS): 160U Magnesium chloride: 100mg Reagent (3) (colipase) Standard solution) Dilute 30000U / mg colipase in physiological saline to obtain 5,10,1
It was diluted to 5,20,25,30,35,40 ng / ml.
(B)測定方法 前項で調製した試薬(1)を1.1ml試験管に350μl、
試薬(3)または精製水を20μl採取し、37℃で5分間
加温する。次に試薬(2)を50μl加え、3分〜5分目
の吸光度の減少をλ=550nmにて試薬ブランク(前記蒸
留水)を対照に測定する。(B) Measuring method 350 μl of the reagent (1) prepared in the previous section in a 1.1 ml test tube,
Collect 20 μl of reagent (3) or purified water and heat at 37 ° C. for 5 minutes. Next, 50 μl of the reagent (2) is added, and the decrease in the absorbance at 3 minutes to 5 minutes is measured at λ = 550 nm using a reagent blank (the above distilled water) as a control.
1分間当りの吸光度を縦軸に取り検量線を作製したと
ころ良好な直線性を示すグラフが得られた(図面参
照)。When a calibration curve was prepared by plotting the absorbance per minute on the vertical axis, a graph showing good linearity was obtained (see the drawing).
次に試薬(1)に代えて、血清(そのまま)及び膵液
(100倍稀釈液)を同様に処理し、前記検量線によりコ
リパーゼを測定した。その結果を次に示す。Next, instead of the reagent (1), serum (as it was) and pancreatic juice (100-fold diluted solution) were treated in the same manner, and colipase was measured by the above calibration curve. The results are shown below.
*血清 試薬A: 3.1ng/ml 試薬B: 8.5ng/ml 試薬C:23.2ng/ml 試薬D:10.4ng/ml 試薬E: 0.5ng/ml(健常者) *膵液 試薬A:18.3ng/ml 試薬B:32.7ng/ml 試薬C:29.7ng/ml 試薬D: 1.8ng/ml(健常者) 試薬E: 0.4ng/ml(健常者) 〈実施例2〉 (A)試薬 試薬(1) 蒸溜水90mlに非イオン界面活性剤としてエマルゲン70
7(花王アトラス社の商品名、ポリオキシエチレン高級
アルコール)10gを溶解し、ビルダーとして塩化ナトリ
ウム5gを加え室温(25℃)にて攪拌する。この液は濁っ
た状態となるが、そのままトリリノレイン2gを添加し約
2時間激しく攪拌する(トリリノレイン可溶化基質溶
液)。この液を10mMトリス塩酸緩衝液(pH7.9)にて100
倍希釈して透明な水溶液を得た。これに豚由来のリパー
ゼ精製品5000U/dl、10mMデオキシコール酸ナトリウム、
70mM塩化ナトリウム、5mM塩化カルシウムを添加し、試
薬(1)とする(透明なコリパーゼ測定用トリグリセラ
イド基質溶液)。* Serum Reagent A: 3.1ng / ml Reagent B: 8.5ng / ml Reagent C: 23.2ng / ml Reagent D: 10.4ng / ml Reagent E: 0.5ng / ml (healthy person) * Pancreatic juice Reagent A: 18.3ng / ml Reagent B: 32.7 ng / ml Reagent C: 29.7 ng / ml Reagent D: 1.8 ng / ml (healthy person) Reagent E: 0.4 ng / ml (healthy person) <Example 2> (A) Reagent Reagent (1) Distillation Emulgen 70 as a nonionic surfactant in 90 ml of water
7 g (polyoxyethylene higher alcohol, trade name of Kao Atlas) is dissolved, 5 g of sodium chloride is added as a builder, and the mixture is stirred at room temperature (25 ° C). Although this solution becomes cloudy, 2 g of trilinolein is added as it is and stirred vigorously for about 2 hours (trilinolein-solubilized substrate solution). This solution is 100 mM with 10 mM Tris-HCl buffer (pH 7.9).
Diluted twice to obtain a transparent aqueous solution. To this, 5000 U / dl of lipase purified product from pig, 10 mM sodium deoxycholate,
Add 70 mM sodium chloride and 5 mM calcium chloride to obtain reagent (1) (clear triglyceride substrate solution for colipase measurement).
試薬(2) アシルCoAシンセターゼ:5.0U/5ml アデノシン−5′−三リン酸:33.0μmol CoAリチウム塩:7.8μmol 上記試薬を、塩化マグネシウム6水塩5mMを含むトリ
スヒドロキシメチルアミノメタン(pH7.85)溶液に溶解
し試薬(2)とする。Reagent (2) Acyl CoA synthetase: 5.0U / 5ml adenosine-5'-triphosphate: 33.0μmol CoA lithium salt: 7.8μmol Trishydroxymethylaminomethane (pH7.85) containing 5mM magnesium chloride hexahydrate ) Dissolve in solution to give reagent (2).
試薬(3) アシルCoAオキシダーゼ:10.0μ/20ml ペルオキシダーゼ:20.000U/20ml 4−アミノアンチピリン:24μmol 上記試薬を、N−エチル−N−スルホプロピル−m−
トルイジン0.75mMを含む20mM N,N−ビス(2ヒドロキ
シエチル)2−アミノエタンスルホン酸(pH7.30)溶液
に溶解し試薬(3)とする。Reagent (3) Acyl CoA oxidase: 10.0 μ / 20 ml Peroxidase: 20.000 U / 20 ml 4-Aminoantipyrine: 24 μmol The above reagent was added to N-ethyl-N-sulfopropyl-m-
It is dissolved in a 20 mM N, N-bis (2-hydroxyethyl) 2-aminoethanesulfonic acid (pH 7.30) solution containing 0.75 mM toluidine to obtain a reagent (3).
試薬(4) N−エチルマレイミド10mMを塩酸溶液に溶解しpH3.0
としたものを試薬(4)とする。Reagent (4) N-ethylmaleimide 10 mM was dissolved in hydrochloric acid solution to pH 3.0.
This is designated as reagent (4).
(B)測定結果 本測定法の同時再現性を調べるために、前項で調製し
た試薬(1)を1.1ml試験管に採取し、試薬ブランクと
して精製水50μl、検体としてコリパーゼ溶液10ng/ml
と20ng/mlを夫々50μl加え37℃10分間加温する。次に
試薬(2)を1ml加え、30分間反応させた後、試薬
(4)を1ml加え、2分後試薬(3)を加え、室温に放
置後λ550nmにて試薬ブランクを対照に吸光度を測定し
た。また、同様に血清試料の測定をした。(B) Measurement results In order to investigate the simultaneous reproducibility of this measurement method, collect the reagent (1) prepared in the previous section in a 1.1 ml test tube, 50 μl of purified water as a reagent blank, and 10 ng / ml of colipase solution as a sample.
And 20 ng / ml of 50 μl each are added and heated at 37 ° C. for 10 minutes. Next, add 1 ml of reagent (2), react for 30 minutes, add 1 ml of reagent (4), add reagent (3) after 2 minutes, and leave at room temperature, then measure the absorbance at λ550 nm using the reagent blank as a control. did. Also, the serum sample was measured in the same manner.
その結果は次の通りであった。 The results were as follows.
*同時再現性 10ng/ml 20ng/ml (I) 10.1 20.1 (II) 9.9 20.2 (III) 9.9 20.2 (IV) 10.0 20.0 (V) 10.2 19.8 (VI) 9.9 20.1 (VII) 9.7 20.0 (VIII) 10.0 20.1 (IX) 10.1 19.9 (X) 10.1 19.9 *血清 試薬A:18.9ng/ml 試薬B:31.3ng/ml 試薬C: 9.9ng/ml 試薬D:24.8ng/ml 試薬E: 0.2ng/ml(健常者) 〈実施例3〉 (A)試薬 試薬(1) 蒸留水90mlに非イオン界面活性剤としてエマルゲン70
9(花王アトラス社の商品名、ポリオキシエチレン高級
アルコール曇点56℃)10gを溶解し、56℃以上に加熱す
ると液は曇点に達し白濁する。そこへトリオレイン2gを
添加し56℃以上を保ちながら約30分間攪拌し、その後加
熱をやめ攪拌を続けながら放置する。液は室温に近づく
と透明となるので、この透明となった時点で10mMトリス
塩酸緩衝液(pH7.9)にて200倍希釈し、2.5mMデオキシ
コール酸ナトリウム、35mM塩化ナトリウム、豚由来膵リ
パーゼ精製品4000U/dl、3.5mM塩化カルシウムを添加し
試薬(1)とする。* Simultaneous reproducibility 10ng / ml 20ng / ml (I) 10.1 20.1 (II) 9.9 20.2 (III) 9.9 20.2 (IV) 10.0 20.0 (V) 10.2 19.8 (VI) 9.9 20.1 (VII) 9.7 20.0 (VIII) 10.0 20.1 (IX) 10.1 19.9 (X) 10.1 19.9 * Serum Reagent A: 18.9ng / ml Reagent B: 31.3ng / ml Reagent C: 9.9ng / ml Reagent D: 24.8ng / ml Reagent E: 0.2ng / ml (healthy person) ) Example 3 (A) Reagent Reagent (1) Emulgen 70 as a nonionic surfactant in 90 ml of distilled water.
When 9 g of 9 (trade name of Kao Atlas, polyoxyethylene higher alcohol cloud point 56 ° C) is dissolved and heated to 56 ° C or higher, the liquid reaches the cloud point and becomes cloudy. Add 2 g of triolein there and stir for about 30 minutes while maintaining at 56 ° C or higher, then stop heating and leave while stirring. Since the solution becomes transparent as it approaches room temperature, when it becomes transparent, it is diluted 200-fold with 10 mM Tris-HCl buffer (pH 7.9), 2.5 mM sodium deoxycholate, 35 mM sodium chloride, pig-derived pancreatic lipase. Purified product 4000U / dl, 3.5mM calcium chloride is added to make reagent (1).
試薬(2) アシル−CoAシンセターゼ:66U/dl アシル−CoAオキシダーゼ:90U/dl ペルオキシターゼ:16000U/dl ATP:140μmol コエンザイムA:16μmol 10−(3−メトキシカルボキシル・アミノメチル・ベン
ゾイル・カルバモイル)−3.7−ビス(ジメチル−アミ
ノ)−10H−フェノチアジン):2.2μmol 上記試薬を20mMグッド緩衝液(pH6.75)で溶解する。Reagent (2) Acyl-CoA synthetase: 66U / dl Acyl-CoA oxidase: 90U / dl Peroxidase: 16000U / dl ATP: 140μmol Coenzyme A: 16μmol 10- (3-methoxycarboxylaminomethylbenzoylcarbamoyl) -3.7- Bis (dimethyl-amino) -10H-phenothiazine): 2.2 μmol The above reagent is dissolved in 20 mM Good's buffer (pH 6.75).
試薬(3) 検体ブランク用試薬として試薬(1)よりトレオレイ
ン、豚由来膵リパーゼ精製品、塩化カルシウムを抜いた
ものを試薬(3)とする。Reagent (3) As a reagent for sample blank, reagent (3) is prepared by removing treolein, purified product of pancreatic lipase from pig and calcium chloride from reagent (1).
(B)測定結果 実施例で調製した試薬(1)および(3)を各々1ml
試験管に採取し、人血清20μlを(1),(3)に入れ
37℃にて20分間反応させた後試薬(2)を1.5mlを各々
分注し37℃5分後波長666mmにて測定し、試薬(1)を
分注した検体の吸光度を差し引いたリパーゼ活性の吸光
度、及び標準液として20ng/mlのコリパーゼ標準溶液を
調製して求めた人血清コリパーゼの活性は次の通りであ
った。(B) Measurement results 1 ml each of the reagents (1) and (3) prepared in the examples
Collect in a test tube and add 20 μl of human serum to (1) and (3).
After reacting at 37 ° C for 20 minutes, 1.5 ml of each reagent (2) was dispensed, and after 5 minutes at 37 ° C, the wavelength was measured at 666 mm, and the absorbance of the sample dispensed with reagent (1) was subtracted from the lipase activity. And the activity of human serum colipase determined by preparing a standard solution of 20 ng / ml colipase as a standard solution were as follows.
*血清 試薬A: 2.2ng/ml 試薬B:12.2ng/ml 試薬C:20.1ng/ml 試薬D:13.1ng/ml 試薬E: 0.6ng/ml(健常者) 〈実施例4〉 試薬(1) 次の試薬を0.1Mのトリスヒドロキシメチルアミノメタ
ン溶液(pH8.3)15mlに溶解したもの。* Serum Reagent A: 2.2ng / ml Reagent B: 12.2ng / ml Reagent C: 20.1ng / ml Reagent D: 13.1ng / ml Reagent E: 0.6ng / ml (healthy person) <Example 4> Reagent (1) The following reagents were dissolved in 15 ml of 0.1 M trishydroxymethylaminomethane solution (pH 8.3).
4−アミノアンチピリン:5.7mg モノグリセライドリパーゼ:1000U トリオレイン可溶化基質(実施例3):1.7ml 塩化カルシウム:100mg 塩化マグネシウム:8mg 試薬(2) 次に(a)群の試薬を、(b)群で調製した試薬36ml
に溶解したもの。4-Aminoantipyrine: 5.7 mg Monoglyceride lipase: 1000 U Triolein solubilizing substrate (Example 3): 1.7 ml Calcium chloride: 100 mg Magnesium chloride: 8 mg Reagent (2) Next, the reagents of group (a) were added to group (b). 36 ml of the reagent prepared in
Dissolved in.
(a)群: グリセロキナーゼ:5.38U ペルオキシダーゼ:135000U アデノシン三リン酸:42.4mg L−αグリセロリン酸オキシダーゼ:161U アスコルビン酸オキシダーゼ:53.8U (b)群:下記の試薬を蒸留水にて100mlとしpH6.65に
調製したもの。Group (a): Glycerokinase: 5.38U Peroxidase: 135000U Adenosine triphosphate: 42.4mg L-α Glycerophosphate oxidase: 161U Ascorbate oxidase: 53.8U Group (b): The following reagents were made up to 100 ml with distilled water and pH 6 Prepared to .65.
N,Nビス(2−ヒドロキシエチル)2−アミノエタンス
ルフォニックアシッド:4.27g N−エチル−N−スルフォプロピル−m−トルイジン:
0.14g 塩化マグネシウム:3.05g トライトンX−100(ロームアンドハース社の商品名、
ポリオキシエチレンオクチルフェニルエーテル):0.1g (B)測定結果 実施例1で調製したコリパーゼ標準液(20ng/ml)、
または血清サンプルの50μlと、試薬(2)1.5mlを37
℃、5分間反応させ、検体中のグリセロールを消失させ
る。N, N bis (2-hydroxyethyl) 2-aminoethane sulfonic acid: 4.27 g N-ethyl-N-sulfopropyl-m-toluidine:
0.14g Magnesium chloride: 3.05g Triton X-100 (trade name of Rohm and Haas Company,
Polyoxyethylene octyl phenyl ether): 0.1 g (B) measurement results colipase standard solution (20 ng / ml) prepared in Example 1,
Or 50 μl of serum sample and 1.5 ml of reagent (2) 37
Reaction is performed at 5 ° C for 5 minutes to eliminate glycerol in the sample.
次の試薬(1)を1.5ml分注し、37℃、5分間反応さ
せ、15分後、試薬ブランクを対照に、波長550nmにて吸
光度を測定し、ΔEAbsよりコリパーゼの値を求めた結果
は次の通りであった。1.5 ml of the following reagent (1) was dispensed and allowed to react at 37 ° C for 5 minutes. After 15 minutes, the absorbance was measured at a wavelength of 550 nm using the reagent blank as a control, and the value of colipase was calculated from ΔEAbs. It was as follows.
*血清 試薬A: 8.8ng/ml 試薬B: 9.8ng/ml 試薬C:19.6ng/ml 試薬D:14.9ng/ml 試薬E: 0.3ng/ml(健常者) 〈発明の効果〉 この出願に係る透明なコリパーゼ測定用トリグリセラ
イド基質溶液とこれを用いるコリパーゼ活性の測定方法
は以上のように構成したから、従来測定が困難であった
ヒトの膵液、血清等の微量のコリパーゼを高感度に効率
よく測定することができ、膵疾患の早期発見等に貢献す
ることができるという効果を有する。* Serum Reagent A: 8.8ng / ml Reagent B: 9.8ng / ml Reagent C: 19.6ng / ml Reagent D: 14.9ng / ml Reagent E: 0.3ng / ml (healthy person) <Effect of invention> The transparent triglyceride substrate solution for colipase measurement and the method for measuring colipase activity using this solution are configured as described above, so that trace amounts of colipase such as human pancreatic juice and serum, which have been difficult to measure in the past, can be measured with high sensitivity and high efficiency. This has the effect of contributing to early detection of pancreatic diseases and the like.
図面は、コリパーゼ活性の検量線を示すグラフである。 The drawing is a graph showing a calibration curve of colipase activity.
Claims (9)
化水溶液にリパーゼを含有させると共に、更にこれに胆
汁酸、塩化カルシウム等のリパーゼ機能促進物質を含有
させたことを特徴とする透明なコリパーゼ測定用トリグ
リセライド基質溶液。1. A uniform and soluble triglyceride (transparent).
A transparent triglyceride substrate solution for colipase measurement, which comprises adding lipase to a chlorinated aqueous solution and further containing a lipase function-promoting substance such as bile acid and calcium chloride.
化水溶液を調製するために使用した界面活性剤が、非イ
オン界面活性剤である特許請求の範囲第1項記載の透明
なコリパーゼ測定用トリグリセライド基質溶液。2. A uniform and soluble triglyceride (transparent).
The transparent triglyceride substrate solution for measuring colipase according to claim 1, wherein the surfactant used for preparing the cationized aqueous solution is a nonionic surfactant.
ン誘導体である特許請求の範囲第2項記載の透明なコリ
パーゼ測定用トリグリセライド基質溶液。3. The transparent triglyceride substrate solution for measuring colipase according to claim 2, wherein the nonionic surfactant is a polyoxyethylene derivative.
特許請求の範囲第2項記載の透明なコリパーゼ測定用ト
リグリセライド基質溶液。4. The transparent triglyceride substrate solution for measuring colipase according to claim 2, wherein the nonionic surfactant is HLB10-16.
原子数が、12〜22個である特許請求の範囲第1項記載の
透明なコリパーゼ測定用トリグリセライド基質溶液。5. The transparent triglyceride substrate solution for measuring colipase according to claim 1, wherein the fatty acid constituting the triglyceride has 12 to 22 carbon atoms.
化水溶液のリパーゼの含有量が、測定対象である生体試
料のリパーゼ含有量より多量である特許請求の範囲第1
〜5項記載の透明なコリパーゼ測定用トリグリセライド
基質溶液。6. A uniform and soluble triglyceride (transparent)
The lipase content of the modified aqueous solution is larger than the lipase content of the biological sample to be measured.
5. A transparent triglyceride substrate solution for measuring colipase according to item 5.
用トリグリセライド基質溶液に、コリパーゼ活性未知の
コリパーゼを含有する試料を作用させて遊離する脂肪酸
またはグリセロールを、従来公知の吸光度測定法により
定量し、この定量値からコリパーゼ活性を測定すること
を特徴とする透明なコリパーゼ測定用トリグリセライド
基質溶液を用いたコリパーゼ活性の測定方法。7. A transparent triglyceride substrate solution for lipase measurement containing a lipase-containing triglyceride substrate solution, and a fatty acid or glycerol liberated by allowing a sample containing a lipase-containing colipase to act thereon is quantified by a conventionally known absorbance measurement method. A method for measuring colipase activity using a transparent triglyceride substrate solution for measuring colipase, which comprises measuring colipase activity from a quantitative value.
酸(ATP)、及びコエンザイムA(CoA)の存在下にアル
シコエンザイムAシンセターゼ(ACS)を反応させて生
成する、(1)アデノシン1リン酸(AMP)、(2)ア
シルCoA、または(3)前記反応において残存するCoAの
うちの一成分を、従来公知の吸光度測定法により定量
し、この定量値からコリパーゼ活性を測定する特許請求
の範囲第(VII)項記載の透明なコリパーゼ測定用トリ
グリセライド基質溶液を用いたコリパーゼ活性の測定方
法。8. (1) Adenosine monophosphate, which is produced by reacting liberated fatty acid with Arsicoenzyme A synthetase (ACS) in the presence of adenosine triphosphate (ATP) and coenzyme A (CoA). Claims: (AMP), (2) acyl CoA, or (3) one component of CoA remaining in the above reaction is quantified by a conventionally known absorbance measurement method, and colipase activity is measured from this quantified value. A method for measuring colipase activity using the transparent triglyceride substrate solution for measuring colipase according to item (VII).
反応系にモノグリセライドリパーゼを更に存在させる特
許請求の範囲第(VII)項記載の透明なコリパーゼ測定
用トリグリセライド基質溶液を用いたコリパーゼ活性の
測定方法。9. When detecting free glycerol,
The method for measuring colipase activity using the transparent triglyceride substrate solution for measuring colipase according to claim (VII), wherein monoglyceride lipase is further present in the reaction system.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17812488A JPH082318B2 (en) | 1988-07-19 | 1988-07-19 | Transparent triglyceride substrate solution for measuring colipase and method for measuring colipase activity using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17812488A JPH082318B2 (en) | 1988-07-19 | 1988-07-19 | Transparent triglyceride substrate solution for measuring colipase and method for measuring colipase activity using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0227998A JPH0227998A (en) | 1990-01-30 |
| JPH082318B2 true JPH082318B2 (en) | 1996-01-17 |
Family
ID=16043072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP17812488A Expired - Fee Related JPH082318B2 (en) | 1988-07-19 | 1988-07-19 | Transparent triglyceride substrate solution for measuring colipase and method for measuring colipase activity using the same |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH082318B2 (en) |
-
1988
- 1988-07-19 JP JP17812488A patent/JPH082318B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0227998A (en) | 1990-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4543326A (en) | Stabilization of oxidase | |
| Wahlefeld | Triglycerides determination after enzymatic hydrolysis | |
| EP0019253B1 (en) | Test device, composition and method for the determination of triglycerides | |
| Mizuno et al. | A new enzymatic method for colorimetric determination of free fatty acids | |
| EP1813680B1 (en) | Compositions for lipase activity determination and method of determining activity | |
| US4394445A (en) | Enzymatic glyceride hydrolysis | |
| US5082769A (en) | Aqueous solution of triglyceride substrate for determination of lipase | |
| US4503146A (en) | Method for eliminating turbidity in a biological fluid and reagent therefor | |
| EP0016799A1 (en) | Determination of triglycerides and enzyme reagents | |
| US4022667A (en) | Substrate solution for carboxylic ester hydrolase determination | |
| JPH082318B2 (en) | Transparent triglyceride substrate solution for measuring colipase and method for measuring colipase activity using the same | |
| US4279994A (en) | Lipase determination method and reagent | |
| US4816411A (en) | Method for eliminating turbidity in a biological fluid and reagent therefor | |
| GB2084726A (en) | Reagent for reducing turbidity in a biological fluid | |
| US4007091A (en) | Method for measuring the activity of lecithin cholesterol acyl transferase and lecithin substrate solution useful therefor | |
| JPH082317B2 (en) | Method for measuring human pancreatic lipase activity | |
| JP4013108B2 (en) | Method for stabilizing lipase | |
| Salvayre et al. | Fluorometric assay for pancreatic lipase. | |
| JPH0367600A (en) | Unifunctional reagent for determination of lipase and method of its preparation | |
| JP2894710B2 (en) | Pancreatic lipase activity measurement method | |
| CA1201047A (en) | Method for quantitative measurement of phosphatidyl glycerol | |
| JP3760250B2 (en) | Method for quantifying sulfate-conjugated bile acids and kits thereof | |
| JPH05123194A (en) | Composition for measuring lipase activity and method for measuring lipase activity using the same composition | |
| EP0019875B1 (en) | Method for assaying fatty acids | |
| JP3868214B2 (en) | Stabilization of liquid catalase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |